Download PDF
Semin Neurol 2023; 43(05): 799-806
DOI: 10.1055/s-0043-1775791
Review Article

Disease-Based Prognostication: Myasthenia Gravis

Jorge L. Almodovar 
1   Department of Neurology, University of North Carolina School of Medicine, Chapel Hill, North Carolina
,
Anahit Mehrabyan
1   Department of Neurology, University of North Carolina School of Medicine, Chapel Hill, North Carolina
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Myasthenia gravis (MG) is an acquired autoimmune neuromuscular junction transmission disorder that clinically presents as fluctuating or persistent weakness in various skeletal muscle groups. Neuroprognostication in MG begins with some basic observations on the natural history of the disease and known treatment outcomes. Our objective is to provide a framework that can assist a clinician who encounters the MG patient for the first time and attempts to prognosticate probable outcomes in individual patients. In this review article, we explore clinical type, age of onset, antibody status, severity of disease, thymus pathology, autoimmune, and other comorbidities as prognostic factors in MG.

Keywords

myasthenia gravis - prognostication - outcomes


Publication History

Article published online:
26 September 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002; 2 (10) 797-804
    CrossrefPubMedGoogle Scholar
  • 2 Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 2015; 14 (10) 1023-1036
    CrossrefPubMedGoogle Scholar
  • 3 Jaretzki III A, Barohn RJ, Ernstoff RM. et al; Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Myasthenia gravis: recommendations for clinical research standards. Neurology 2000; 55 (01) 16-23
    CrossrefPubMedGoogle Scholar
  • 4 Benatar M, Sanders DB, Burns TM. et al; Task Force on MG Study Design of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Recommendations for myasthenia gravis clinical trials. Muscle Nerve 2012; 45 (06) 909-917
    CrossrefPubMedGoogle Scholar
  • 5 Baggi F, Andreetta F, Maggi L. et al. Complete stable remission and autoantibody specificity in myasthenia gravis. Neurology 2013; 80 (02) 188-195
    CrossrefPubMedGoogle Scholar
  • 6 Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008; 37 (02) 141-149
    CrossrefPubMedGoogle Scholar
  • 7 Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord 2019; 12: 1756286419832242
    CrossrefPubMedGoogle Scholar
  • 8 Bever Jr CT, Aquino AV, Penn AS, Lovelace RE, Rowland LP. Prognosis of ocular myasthenia. Ann Neurol 1983; 14 (05) 516-519
    CrossrefPubMedGoogle Scholar
  • 9 Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 1989; 52 (10) 1121-1127
    CrossrefPubMedGoogle Scholar
  • 10 Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 2003; 60 (02) 243-248
    CrossrefPubMedGoogle Scholar
  • 11 Sommer N, Sigg B, Melms A. et al. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 1997; 62 (02) 156-162
    CrossrefPubMedGoogle Scholar
  • 12 Punga AR, Maddison P, Heckmann JM, Guptill JT, Evoli A. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol 2022; 21 (02) 176-188
    CrossrefPubMedGoogle Scholar
  • 13 Schroeter M, Thayssen G, Kaiser J. Myasthenia gravis—exacerbation and crisis. Neurol Int Open 2018; 02: E10-E15
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Mazzoli M, Ariatti A, Valzania F. et al. Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci 2018; 128 (01) 15-24
    CrossrefPubMedGoogle Scholar
  • 15 Wang L, Zhang Y, He M. Clinical predictors for the prognosis of myasthenia gravis. BMC Neurol 2017; 17 (01) 77
    CrossrefPubMedGoogle Scholar
  • 16 Vijayan J, Menon D, Barnett C, Katzberg H, Lovblom LE, Bril V. Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis. Muscle Nerve 2021; 64 (04) 462-466
    CrossrefPubMedGoogle Scholar
  • 17 Evoli A, Batocchi AP, Minisci C, Di Schino C, Tonali P. Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr Soc 2000; 48 (11) 1442-1448
    CrossrefPubMedGoogle Scholar
  • 18 Fang F, Sveinsson O, Thormar G. et al. The autoimmune spectrum of myasthenia gravis: a Swedish population-based study. J Intern Med 2015; 277 (05) 594-604
    CrossrefPubMedGoogle Scholar
  • 19 Lazaridis K, Tzartos SJ. Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics. Front Immunol 2020; 11: 212
    CrossrefPubMedGoogle Scholar
  • 20 Verschuuren JJ, Huijbers MG, Plomp JJ. et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev 2013; 12 (09) 918-923
    CrossrefPubMedGoogle Scholar
  • 21 Shelly S, Paul P, Bi H. et al. Improving accuracy of myasthenia gravis autoantibody testing by reflex algorithm. Neurology 2020; 95 (22) e3002-e3011
    CrossrefPubMedGoogle Scholar
  • 22 Shelly S, Mills JR, Dubey D. et al. Clinical utility of striational antibodies in paraneoplastic and myasthenia gravis paraneoplastic panels. Neurology 2021; 96 (24) e2966-e2976
    CrossrefPubMedGoogle Scholar
  • 23 Strijbos E, Verschuuren JJGM, Kuks JBM. Serum acetylcholine receptor antibodies before the clinical onset of myasthenia gravis. J Neuromuscul Dis 2018; 5 (02) 261-264
    CrossrefPubMedGoogle Scholar
  • 24 Ozawa Y, Uzawa A, Yasuda M. et al. Long-term outcomes and prognostic factors in generalized myasthenia gravis. J Neurol 2021; 268 (10) 3781-3788
    CrossrefPubMedGoogle Scholar
  • 25 Murai H. Japanese clinical guidelines for myasthenia gravis: putting into practice. Clin Exp Neuroimmunol 2015; 6: 21-31
    CrossrefPubMedGoogle Scholar
  • 26 Wolfe GI, Kaminski HJ, Aban IB. et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 2016; 375: 511-522
    CrossrefPubMedGoogle Scholar
  • 27 Wolfe GI, Kaminski HJ, Aban IB. et al; MGTX Study Group. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol 2019; 18 (03) 259-268
    CrossrefPubMedGoogle Scholar
  • 28 Cron MA, Maillard S, Villegas J. et al. Thymus involvement in early-onset myasthenia gravis. Ann N Y Acad Sci 2018; 1412 (01) 137-145
    CrossrefPubMedGoogle Scholar
  • 29 Truffault F, de Montpreville V, Eymard B, Sharshar T, Le Panse R, Berrih-Aknin S. Thymic germinal centers and corticosteroids in myasthenia gravis: an immunopathological study in 1035 cases and a critical review. Clin Rev Allergy Immunol 2017; 52 (01) 108-124
    CrossrefPubMedGoogle Scholar
  • 30 Sarkkinen J, Dunkel J, Tuulasvaara A. et al. Ectopic germinal centers in the thymus accurately predict prognosis of myasthenia gravis after thymectomy. Mod Pathol 2022; 35 (09) 1168-1174
    CrossrefPubMedGoogle Scholar
  • 31 Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7 (03) 365-368
    CrossrefPubMedGoogle Scholar
  • 32 Bartoccioni E, Scuderi F, Minicuci GM, Marino M, Ciaraffa F, Evoli A. Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 2006; 67 (03) 505-507
    CrossrefPubMedGoogle Scholar
  • 33 Huang Q, Li F, Zhao S. Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes. BMC Neurol 2022; 22 (01) 73
    CrossrefPubMedGoogle Scholar
  • 34 Zhao S, Zhang K, Ren K. et al. Clinical features, treatment and prognosis of MuSK antibody-associated myasthenia gravis in Northwest China: a single-centre retrospective cohort study. BMC Neurol 2021; 21 (01) 428
    CrossrefPubMedGoogle Scholar
  • 35 Zhou L, McConville J, Chaudhry V. et al. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve 2004; 30 (01) 55-60
    CrossrefPubMedGoogle Scholar
  • 36 Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011; 44 (01) 36-40
    CrossrefPubMedGoogle Scholar
  • 37 Farrugia ME, Robson MD, Clover L. et al. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 2006; 129 (Pt 6): 1481-1492
    CrossrefPubMedGoogle Scholar
  • 38 Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A, Ströbel P. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 2013; 12 (09) 875-884
    CrossrefPubMedGoogle Scholar
  • 39 Sanders DB, Juel VC. MuSK-antibody positive myasthenia gravis: questions from the clinic. J Neuroimmunol 2008; 201–202: 85-89
    CrossrefPubMedGoogle Scholar
  • 40 Hehir MK, Hobson-Webb LD, Benatar M. et al. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. Neurology 2017; 89 (10) 1069-1077
    CrossrefPubMedGoogle Scholar
  • 41 Kim N, Stiegler AL, Cameron TO. et al. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 2008; 135 (02) 334-342
    CrossrefPubMedGoogle Scholar
  • 42 Yu Z, Zhang M, Jing H. et al. Characterization of LRP4/Agrin antibodies from a patient with myasthenia gravis. Neurology 2021; 97 (10) e975-e987
    CrossrefPubMedGoogle Scholar
  • 43 Rivner MH, Quarles BM, Pan JX. et al. Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: a multicenter study. Muscle Nerve 2020; 62 (03) 333-343
    CrossrefPubMedGoogle Scholar
  • 44 Romi F, Hong Y, Gilhus NE. Pathophysiology and immunological profile of myasthenia gravis and its subgroups. Curr Opin Immunol 2017; 49: 9-13
    CrossrefPubMedGoogle Scholar
  • 45 Romi F, Gilhus NE, Varhaug JE, Myking A, Aarli JA. Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study. Eur J Neurol 2003; 10 (06) 701-706
    CrossrefPubMedGoogle Scholar
  • 46 Comacchio GM, Marulli G, Mammana M, Natale G, Schiavon M, Rea F. Surgical decision making: thymoma and myasthenia gravis. Thorac Surg Clin 2019; 29 (02) 203-213
    CrossrefPubMedGoogle Scholar
  • 47 Álvarez-Velasco R, Gutiérrez-Gutiérrez G, Trujillo JC. et al. Clinical characteristics and outcomes of thymoma-associated myasthenia gravis. Eur J Neurol 2021; 28 (06) 2083-2091
    CrossrefPubMedGoogle Scholar
  • 48 Sanders DB, Wolfe GI, Benatar M. et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016; 87 (04) 419-425
    CrossrefPubMedGoogle Scholar
  • 49 Narayanaswami P, Sanders DB, Wolfe G. et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 2021; 96 (03) 114-122
    CrossrefPubMedGoogle Scholar
  • 50 Howard Jr JF, Utsugisawa K, Benatar M. et al; REGAIN Study Group. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. [published correction appears in Lancet Neurol. 2017 Dec;16(12):954] Lancet Neurol 2017; 16 (12) 976-986
    CrossrefPubMedGoogle Scholar
  • 51 Vu T, Meisel A, Mantegazza R. et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid 2022; 1: 2100066
    PubMedGoogle Scholar
  • 52 Cutter G, Xin H, Aban I. et al. Cross-sectional analysis of the myasthenia gravis patient registry: disability and treatment. Muscle Nerve 2019; 60 (06) 707-715
    CrossrefPubMedGoogle Scholar
  • 53 Hansen JS, Danielsen DH, Somnier FE. et al. Mortality in myasthenia gravis: a nationwide population-based follow-up study in Denmark. Muscle Nerve 2016; 53 (01) 73-77
    CrossrefPubMedGoogle Scholar
  • 54 Jeong S, Noh Y, Oh IS, Hong YH, Shin JY. Survival, prognosis, and clinical feature of refractory myasthenia gravis: a 15-year nationwide cohort study. J Korean Med Sci 2021; 36 (39) e242
    CrossrefPubMedGoogle Scholar
  • 55 Jani-Acsadi A, Lisak RP. Myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci 2007; 261 (1–2): 127-133
    CrossrefPubMedGoogle Scholar
  • 56 Thomas CE, Mayer SA, Gungor Y. et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997; 48 (05) 1253-1260
    CrossrefPubMedGoogle Scholar
  • 57 Sakaguchi H, Yamashita S, Hirano T. et al. Myasthenic crisis patients who require intensive care unit management. Muscle Nerve 2012; 46 (03) 440-442
    CrossrefPubMedGoogle Scholar
  • 58 Nelke C, Stascheit F, Eckert C. et al. Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients. J Neuroinflammation 2022; 19 (01) 89
    CrossrefPubMedGoogle Scholar
  • 59 Neumann B, Angstwurm K, Mergenthaler P. et al. Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases. [published correction appears in Neurology. 2020 Apr 21;94(16):724. Schneider, Haucke [corrected to Schneider, Hauke]]. Neurology 2020; 94 (03) e299-e313
    CrossrefPubMedGoogle Scholar
  • 60 Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 2009; 72 (18) 1548-1554
    CrossrefPubMedGoogle Scholar
  • 61 König N, Stetefeld HR, Dohmen C. et al; German Myasthenic Crisis Study Group. MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation. J Neurol 2021; 268 (12) 4824-4833
    CrossrefPubMedGoogle Scholar
  • 62 Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis 2007; 2: 44
    CrossrefPubMedGoogle Scholar
  • 63 Chiang LM, Darras BT, Kang PB. Juvenile myasthenia gravis. Muscle Nerve 2009; 39 (04) 423-431
    CrossrefPubMedGoogle Scholar
  • 64 Wang H, Su Z, Luo C. et al. The effect of steroid treatment and thymectomy on bone age and height development in juvenile myasthenia gravis. Neurol Sci 2013; 34 (12) 2173-2180
    CrossrefPubMedGoogle Scholar
  • 65 Li Z, Li F, Zhang H. et al. Outcomes of juvenile myasthenia gravis: a comparison of robotic thymectomy with medication treatment. Ann Thorac Surg 2022; 113 (01) 295-301
    CrossrefPubMedGoogle Scholar
  • 66 Gilhus NE, Nacu A, Andersen JB, Owe JF. Myasthenia gravis and risks for comorbidity. Eur J Neurol 2015; 22 (01) 17-23
    CrossrefPubMedGoogle Scholar
  • 67 Laakso SM, Myllynen C, Strbian D, Atula S. Comorbidities worsen the prognosis of generalized myasthenia gravis post-thymectomy. J Neurol Sci 2021; 427: 117549
    CrossrefPubMedGoogle Scholar
  • 68 Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. Centers for Disease Control and Prevention. October 22, 2022. Accessed October, 27, 2022 at: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html
    PubMed
  • 69 People with Certain Medical Conditions. Centers for Disease Control and Prevention. October 19, 2022. Accessed October 27, 2022 at: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html
    PubMed
  • 70 Camelo-Filho AE, Silva AMS, Estephan EP. et al. Myasthenia gravis and COVID-19: clinical characteristics and outcomes. Front Neurol 2020; 11: 1053
    CrossrefPubMedGoogle Scholar
  • 71 Muppidi S, Guptill JT, Jacob S. et al; CARE-MG Study Group. COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurol 2020; 19 (12) 970-971
    CrossrefPubMedGoogle Scholar
  • 72 Gungor Tuncer O, Deymeer F. Clinical course and outcome of an outpatient clinic population with myasthenia gravis and COVID-19. Muscle Nerve 2022; 65 (04) 447-452
    CrossrefPubMedGoogle Scholar